US-based brain-computer interface (BCI) startup Precision Neuroscience has acquired a microelectromechanical systems (MEMS) factory, located near Dallas, Texas.

Precision completed the facility acquisition through its subsidiary Precision BioMEMS.

The 22,000 ft2 facility includes a 5,500 ft2 ISO Class-5 clean room for manufacturing, over 500ft2 of ISO Class-6 post-processing and assembly space, and 50 specialised tools.

Precision BioMEMS has retained the employees at the facility, who have in-depth knowledge of both biomedical and general-purpose MEMS manufacturing.

In addition, the neurotech company announced that the US Food and Drug Administration has granted Breakthrough Device designation for its system.

Precision CEO Michael Mager said: “To deliver brain-computer interface technology to the millions of people who stand to benefit, we need to rethink the medical device supply chain.

“High-precision microfabrication is critical to building powerful brain-computer interfaces, and it will play an increasingly important role in medical device manufacturing going forward.

“Precision BioMEMS will help us build the neural technology of tomorrow while also advancing the broader US medical device industry.”

Precision said that the facility purchase facilitates an in-house supply chain and strengthens its position as one of the top manufacturers of biomedical MEMS in the US.

The company will get full control of its core technology, dubbed Layer 7 Cortical Interface, along with quality management and development of future versions.

Layer 7 Cortical Interface is a thin-film microelectrode array that facilitates packing 1,024 electrodes into 1.5cm2 of area.

Established in 2021, Precision is engaged in developing a BCI that is minimally invasive, safely removable, and capable of processing large amounts of data.

Earlier this year, the company completed the first-in-human procedures of its neural implant system, Layer 7 Cortical Interface, in a pilot clinical study.

Its brain implant will help restore brain function in people suffering from neurological disorders, such as speech deficits and paralysis, said the medical device company.